ReSitu Medical has received a 50,000 Euro grant from the EIT Health Headstart programme.
The Headstart programme aims to help start-ups get closer to market, achieve clinical verification of their innovation, evaluate patient need and benefit, as well as attracting further private investment.
“We are so thankful to EIT for this opportunity to be part of this great programme and I am looking forward to the outcome of the project which will help us drive our innovation forward,” says Per Hedén, Associate Professor of Plastic Surgery at Karolinska Institute, Stockholm and co- founder of the company.
Innovative solution for tumor biopsies
ReSitu utilizes high resolution ultrasound (HRUS) to reach the tumor site, and a minimally invasive blunt penetration technique and standard electrocautery energy to remove tumors without bleeding. The project will be headed by CEO Stefan Sowa and ReSitu Medical’s team of expert consultants will work to develop a technology for breast cancer diagnosis and treatment. In addition, it will offer cost savings and easy handling and thus be competitive as well as affordable even for poorer countries, states the company.
To date, the company has had an injection of 5 million SEK from private investors.
“ReSitu has a very innovative solution for tumor biopsies, saving precious healthcare time and cost and allowing for faster patient recovery. I am proud that EIT Health are able to support them and help them accelerate their development and time to market. In the long term, we believe that they will be able to significantly improve the lives of patients and citizens,” says Erik Forsberg, Managing Director of EIT Health Scandinavia.
Photo of Per Hedén, co-founder of ReSitu Medical AB and Associate Professor of Plastic Surgery at Karolinska Institute, Stockholm